Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512096 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00512096: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00512096 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512096, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Primary Outcome
Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions.
Interventions
- DRUG Cisplatin
- DRUG Ifosfamide
- DRUG Paclitaxel (Taxol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-08 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00512096 record still lists
NCT00512096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00512096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00512096 about?
NCT00512096 is a clinical study titled "Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis". Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
What is the current status of trial NCT00512096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-08. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00512096?
The interventions under investigation include: Cisplatin (DRUG), Ifosfamide (DRUG), Paclitaxel (Taxol) (DRUG).
Who is sponsoring clinical trial NCT00512096?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00512096's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia